BMJ Open 'Give Us The Tools!': development of knowledge transfer tools to support the involvement of patient partners in the development of clinical trial protocols with patient-reported outcomes (PROs), in accordance with SPIRIT-PRO Extension

Samantha Cruz Rivera ¹, Richard Stephens,² Rebecca Mercieca-Bebber ³, Ameeta Retzer,¹ Claudia Rutherford,⁴ Gary Price,¹ Anita Slade,¹ Olalekan Lee Aiyegbusi,¹ Philip Edge,⁵ Lesley Roberts,^{1,5} Lesley Gosden,⁵ Rav Verdi,⁵ Roger Wilson,⁶ Melanie Calvert ¹

To cite: Cruz Rivera S, Stephens R, Mercieca-Bebber R, *et al.* 'Give Us The Tools!': development of knowledge transfer tools to support the involvement of patient partners in the development of clinical trial protocols with patient-reported outcomes (PROs), in accordance with SPIRIT-PRO Extension. *BMJ Open* 2021;**11**:e046450. doi:10.1136/bmjopen-2020-046450

► Prepublication history and supplemental material for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2020-046450>).

Received 03 November 2020
Revised 07 January 2021
Accepted 08 January 2021

Linked
► <http://dx.doi.org/10.1136/bmjopen-2020-045105>

Check for updates

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Professor Melanie Calvert;
M.Calvert@bham.ac.uk

ABSTRACT

Objectives (a) To adapt the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)-patient-reported outcome (PRO) Extension guidance to a user-friendly format for patient partners and (b) to codesign a web-based tool to support the dissemination and uptake of the SPIRIT-PRO Extension by patient partners.

Design A 1-day patient and public involvement session.

Participants Seven patient partners.

Methods A patient partner produced an initial lay summary of the SPIRIT-PRO guideline and a glossary. We held a 1-day PPI session in November 2019 at the University of Birmingham. Five patient partners discussed the draft lay summary, agreed on the final wording, codesigned and agreed the final content for both tools. Two additional patient partners were involved in writing the manuscript. The study compiled with INVOLVE guidelines and was reported according to the Guidance for Reporting Involvement of Patients and the Public 2 checklist.

Results Two user-friendly tools were developed to help patients and members of the public be involved in the codesign of clinical trials collecting PROs. The first tool presents a lay version of the SPIRIT-PRO Extension guidance. The second depicts the most relevant points, identified by the patient partners, of the guidance through an interactive flow diagram.

Conclusions These tools have the potential to support the involvement of patient partners in making informed contributions to the development of PRO aspects of clinical trial protocols, in accordance with the SPIRIT-PRO Extension guidelines. The involvement of patient partners ensured the tools focused on issues most relevant to them.

INTRODUCTION

Patient-reported outcomes (PROs) provide information about the status of a patient's

Strengths and limitations of this study

- Two user-friendly tools were codeveloped with patient and public involvement (PPI) partners for the use of patient partners involved in the codesign of clinical trials collecting patient-reported outcomes.
- The research was reported according to Guidance for Reporting Involvement of Patients and the Public 2 checklist and adhered to INVOLVE recommendations.
- The user-friendly tools were not tested among a wider patient partner group.
- In addition, the PPI partners included in the codevelopment of the tools were mainly oncology patients.

health, directly from the patient, without interpretation by a clinician.¹ PROs are collected in clinical trials to provide evidence of the impact of disease treatment on functional health, well-being, severity of symptoms or side effects, and psychological impact of the disease and/or the treatment.²

Clinical trials are medical research studies carried out to determine the activity, safety, efficacy, effectiveness and adverse effects of diagnostic and therapeutic interventions.³ Clinical trial protocols describe the objective(s), design, procedures and statistical considerations needed to conduct a specific clinical trial. Recent research suggests important PRO protocol-items, such as hypotheses, data collection methods and statistical plans are often missing from trial protocols.^{4–7} Furthermore, rates of avoidable

missing PRO data are often high^{4 5 8} and PRO data publications are reported long after other outcomes or not at all^{9 10}; if reported, the PRO reporting is often inadequate.^{7-9 11-14}

A recent review of 228 National Institute of Health Research Cancer portfolio studies identified that PRO data were left unreported for studies involving nearly 50 000 patients, which is unacceptable and unethical.⁹ Moreover, such failures and omissions compromise the impact of PROs on future patient care and health policy, and also waste valuable resources in terms of patient and researcher time and funding.

In 2018, the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials)-PRO Extension was published with the aim to provide recommendations for researchers on which items should be addressed in clinical trial protocols with primary or key secondary PRO endpoints. However, there is a lack of training materials and tools to support the uptake of the SPIRIT-PRO guidance to promote quality and to simplify the approach for patient partners who are involved in the review and

codesign of clinical trials with PRO objectives.¹⁵ The aim of this research was to: (a) adapt the SPIRIT-PRO Extension guidance to a user-friendly format for patient partners and (b) codesign a web-based tool to support the dissemination and uptake of the SPIRIT-PRO Extension by patient partners.

METHODS

A patient partner (GP) produced an initial lay summary of the SPIRIT-PRO guideline and drafted a glossary with support from academic coauthors (MC and SCR). The patient partner selected to produce the initial lay summary and glossary was originally involved in the development of the SPIRIT-PRO Extension guideline. In addition, the patient partner has experienced completing PRO questionnaires and has been involved in different PRO-specific projects to provide his perspective from a patient's perspective.

A 1-day PPI (patient and public involvement) session was held with patient partners in November 2019 at the University of Birmingham, UK. The aim of the PPI session was to adapt the SPIRIT-PRO Extension guidance to a user-friendly format for patient partners, and codesign a tool to aid patient partners in the codesign of PRO clinical trials. The PPI session was conducted and reported according to the Guidance for Reporting Involvement of Patients and the Public (GRIPP) 2 reporting checklists. This international provides guidance on the key reporting items for reporting PPI in health and social care research.¹⁶ In addition, the PPI session complied with the INVOLVE guideline, a government supported programme that promotes active public involvement in National Health Service, public health and social care research.¹⁷

Patient and public involvement

Seven PPI partners who were already known to the team, who had relevant experience in clinical trials, were recruited by the research team to assist at different stages in the development of the tools. The PPI partners were six patients and one carer with personal experience of different health conditions including oncology (four PPI partners), Parkinson's (one PPI partner) and chronic kidney disease (one PPI partner). Six PPI partners identified themselves as white and one as Sikh British. Only three of the PPI partners were previously involved as trial participants. One partner was involved in the development of the first version of the patient-friendly SPIRIT-PRO guidance. Five were involved in the codesign of the patient-friendly SPIRIT-PRO tools, and all seven contributed to writing this manuscript.

During the session, five PPI partners (GP/LR/LG/RV/PE) and two academics (MC and SCR) discussed the original SPIRIT-PRO Extension guideline and contrasted it with the initial lay summary drafted. PPI partners commented on the comprehension and refined and agreed the wording and clarity of the lay version of the

Figure 1 User-friendly SPIRIT-PRO Extension and glossary methods. PPI, patient and public involvement; PRO, patient-reported outcome; SPIRIT, Standard Protocol Items: Recommendations for Interventional Trials.

Table 1 User-friendly version of the SPIRIT-PRO Extension guidance

SPIRIT-PRO item number and description	Questions for PPI partner(s) to consider	Key considerations for PPI partner(s)	Considerations for the lay summary	Considerations for participant information sheet and consent form
Administrative information				
SPIRIT-5a-PRO Elaboration: specify the individual(s) responsible for the PRO content of the trial protocol	Are PPI partners being involved in the codesign of trials involving PROs? (Are they patients or carers; are there different considerations?)	<ul style="list-style-type: none"> ▲ PPI partners who have made a significant contribution to the trial protocol should be acknowledged.¹⁶ ▲ Specify PPI partner role: coapplicant, trial management group or coproduction. 		
Introduction				
SPIRIT-6a-PRO Elaboration: describe the PRO-specific research question and rationale for PRO assessment and summarise PRO findings in relevant studies	Is the research team collecting PROs? If not, why not? If yes, do the team have a clear reason for assessing PROs in the trial? Have the team specified their goals in assessing PROs?	<ul style="list-style-type: none"> ▲ PPI partners can help to prioritise research questions. ▲ What is the purpose of collecting the PRO data? ▲ Has the research team explained to you (and in the protocol) about the likely effect of treatment on participants' symptoms, function and quality of life? If likely to be impacted by the intervention during the clinical trial. ▲ Can the clinical team draw a graph showing quality of life progression for standard care vs new treatment for the duration of the trial? Does this match your experience as patient (or carer)? ▲ What evidence do they have to support this? 	Has the research team looked at the literature around previous trials, qualitative work or COS (core outcome sets) on what matters to the patient (or carer)?	Describe the PRO specific research question and rationale for PRO assessment, and summarise PRO findings in relevant studies.
SPIRIT-7-PRO Elaboration: state specific PRO objectives or hypotheses (including relevant PRO concepts/domains)				
	Has the research team clearly stated the purpose of the research?	<ul style="list-style-type: none"> ▲ How do they plan to use the PRO data that they collect during and at the end of the trial? For instance, to inform clinical practice, inform future patient care and inform NICE (National Institute for Health and Care Excellence) policy or health economics. 	It is important that lay summary clearly describe the purpose of assessing PROs in the trial.	Include the purpose of assessing PROs in the trial.
Methods: participants, interventions and outcomes				
SPIRIT-10-PRO Elaboration: specify any PRO-specific eligibility criteria (eg, language/reading requirements or preredominant completion of PRO). If PROs will not be collected from the entire study sample, provide a rationale and describe the method for obtaining the PRO subsample	Are there any specific reasons why a participant might not be able to complete the PRO questionnaire?	<ul style="list-style-type: none"> ▲ PPI partners can provide advice to the research team on whether patients (or carers) are likely to be able to complete PROs in the trial. For example, some may be unable to complete them because of poor literacy, language, communication difficulties. Because their condition, or cultural or cognition considerations. ▲ Consider whether these participants need to be excluded from the PRO study or trial. Try to be as inclusive as possible ▲ It is important to consider that <i>proxy completion</i> (report of the patient health status by his/her carer or clinician or parents reporting on behalf of children) can be an option in some cases—please see SPIRIT-PRO 18a(iv) below. 		Has data protection been taken into consideration if <i>proxy completion</i> is a possibility?

Continued

Table 1 Continued

SPRIT-PRO item number and description	Questions for PPI partner(s) to consider	Key considerations for PPI partner(s)	Considerations for the lay summary	Considerations for participant information sheet and consent form
SPRIT-12-PRO Elaboration: specify the PRO concepts/domains used to evaluate the intervention (eg, overall health-related quality of life, specific domain, specific symptom) and, for each one, the analysis metric (eg, change from baseline, final value, time to event) and the principal time point or period of interest	Has the team specified exactly what is going to be measured? How and when do they plan to do this? For example, physical function, pain and/or HRQL, etc.	<ul style="list-style-type: none"> ▲ PPI partners can work with the broader research team to help determine which PROs (eg, symptoms, side effects, aspects of functioning or mental health) patients or carers should report on and how often these will be assessed. 		Include what questionnaire(s) are going to be completed during the trial.
SPRIT-13-PRO Elaboration: include a schedule of PRO assessments, providing a rationale for the time points, and justifying if the initial assessment is not prerandomisation. Specify time windows, whether PRO collection is prior to clinical assessments, and, if using multiple questionnaires, whether order of administration will be standardised	How often will participants be asked to complete the questionnaire(s)?	<ul style="list-style-type: none"> ▲ PPI partners can help determine whether the frequency of PRO assessments is likely to be feasible for patients or carers. If it is frequent is this likely to be a burden, and if so, will it cause drop out or failure to respond? ▲ Is the time between assessment too long and likely to miss important events that matter to patients or carers? ▲ PPI partners can provide feedback on the most important time-points to collect PROs based on their own experience of the condition or treatment. ▲ How long will participants have to return the questionnaire? Is the timeframe too short—will participants have time to complete the PRO? Does it need to include a weekend? ▲ Will it coincide with clinic visits or will it take place another time (eg, diaries)? ▲ If trial participants are having tests at clinic or may receive news, try to complete PRO questionnaire before. 		How often are the participants going to be asked to complete the questionnaire(s), when and with what deadlines?
SPRIT-14-PRO Elaboration: when a PRO is the primary end point, state the required sample size (and how it was determined) and recruitment target (accounting for expected loss to follow-up). If sample size is not established based on the PRO end point, then discuss the power of the principal PRO analyses	<p>Is the required number of participants feasible to recruit based on the population being assessed?</p> <p>Are the exclusion criteria too restrictive (ie, they are excluding too many people)?</p> <p>Are there cultural/age related/geography/frailty/language condition/working status reasons why people may not participate or may drop-out?</p>	<p>PPI partners are not expected to assess whether the sample size is adequate, but you may have views on whether people are likely to be interested in participating in the PRO aspects of the trial.</p> <p>If you see something in the protocol that patients or carers might not like then please raise this with the trial team as it may affect whether they have big enough numbers for their study.</p>		
Methods: data collections, management and analysis				

Continued

Table 1 Continued

SPRIT-PRO item number and description	Questions for PPI partner(s) to consider	Key considerations for PPI partner(s)	Considerations for the lay summary	Considerations for participant information sheet and consent form
SPRIT-18a(i)-PRO Elaboration: Justify the PRO instrument to be used and describe domains, number of items, recall period, instrument scaling and scoring (eg, range and direction of scores indicating a good or poor outcome). Evidence of PRO instrument measurement properties, interpretation guidelines, and patient acceptability and burden should be provided or cited if available, ideally in the population of interest. State whether the measure will be used in accordance with any user manual and specify and justify deviations if planned	<p>How did they select the questionnaire (eg, literature, PPI session)?</p> <p>Which questionnaire(s) are they considering using?</p> <p>Does it cover patient priorities?</p> <p>Are the instructions for completion of the questionnaire clear?</p> <p>Can you understand the scoring categories? Are they properly explained and do they make sense?</p>	<p>▲ How appropriate and acceptable are the questionnaires?</p> <p>▲ How long will it take to complete the questionnaire? Trial team should ask PPI partners to complete it to give an estimate.</p> <p>▲ What burden/issues/symptoms/side-effects/aspects of functioning or mental health are relevant in the context of the trial? Are these addressed in the questionnaire?</p> <p>▲ Is the recall/remember period (eg, 1 month or 7 days) appropriate for the condition? For instance, are symptoms stable over time or fluctuating daily (which may require more frequent assessment)?</p>		<p>Include how long is going to take to complete the questionnaire.</p> <p>Are there any questions, such as sexual function, which patients may not wish to answer and may result in missing data?</p> <p>Specify the estimated time to complete each assessment, and discuss feasibility of assessment for the population.</p>
SPRIT-18a(ii)-PRO Elaboration: include a data collection plan outlining the permitted mode(s) of administration (eg, paper, telephone, electronic, other) and setting (eg, clinic, home, other)	<p>Where, when and how will the PRO questionnaire be completed?</p>	<p>▲ PPI partners can help determine the most convenient/practical method to collect PRO data.</p> <p>▲ Where is it going to be collected for example, in clinic at home?</p> <p>▲ Can participants complete on paper/electronically or both?</p> <p>▲ Will all participants be able to do this?</p> <p>▲ Have the team got back up plans for those who cannot complete the PRO in a particular way?</p>		<p>Include a data collection plan outlining the permitted mode(s) of administration (eg, paper, telephone, electronic, other) and setting (eg, clinic, home, other).</p>
SPRIT-18a(iii)-PRO Elaboration: specify whether more than 1 language version will be used and state whether translated versions have been developed using currently recommended methods	<p>What languages are the chosen questionnaire(s) available?</p> <p>Have they got questionnaires available for trial population?</p>	<p>▲ Researchers to make PPI partners aware of the availability of PRO measures in other languages.</p> <p>▲ Are there groups of the population that require a translated version?</p> <p>▲ Have they costed for it?</p> <p>▲ Are they following translation guidelines?</p> <p><i>These are the responsibilities of the trial team but PPI partners may be able to suggest ways of widening inclusivity.</i></p>		

Continued

Table 1 Continued

SPRIT-PRO item number and description	Questions for PPI partner(s) to consider	Key considerations for PPI partner(s)	Considerations for the lay summary	Considerations for participant information sheet and consent form
SPRIT-18a(iv)-PRO Elaboration: when the trial context requires someone other than a trial participant to answer on his or her behalf (a proxy-reported outcome), state and justify the use of a proxy respondent. Provide or cite evidence of the validity of proxy assessment if available	Has the research team made clear whether it is possible for someone other than the patient to complete the questionnaire from the patient's point of view?	<ul style="list-style-type: none"> ▲ Generally, in a trial we prefer to collect PROs directly from the patient as we want to know their views but sometimes a patient cannot complete the questionnaire (eg, if they have memory problems or become too ill). If you think patients may not be able to complete PROs in the trial flag this to the broader research team. ▲ Other things that should be considered: carer reported outcomes. ▲ PPI partners can help provide input on how to collect PRO data and strategies to ensure that participants complete questionnaires as they are scheduled (eg, reminders for patients, training for staff/patients). ▲ Important to provide guidance on PRO completion. 		If it is permissible for another person to help the study participant complete the PROM, describe what type and level of assistance is acceptable.
Ideally researchers should have plans in place to ensure that participants complete questionnaires as they are scheduled	How will the team ensure that data collected is complete? So that it can be used to inform patient care.			
	Can you think of any other ideas that may help promote completion?			
		<ul style="list-style-type: none"> ▲ State why we need as complete data as possible and how it will be used, and where it will be reported (eg, publication). ▲ PPI partners can provide input into developing a process for patients that stop receiving treatment or receive treatment in a way different to planned. This should be linked back to the trial research question. ▲ Consider burden to patients and whether PRO completion is ethical. 		
SPRIT-18b(ii)-PRO Elaboration: describe the process of PRO assessment for participants who discontinue or deviate from the assigned intervention protocol	Is there a plan for collecting data provided by patients who stop receiving the treatment under study (discontinue), or receive the treatment in a way other than planned (deviation)?			
SPRIT-20a-PRO Elaboration: state PRO analysis methods, including any plans for addressing multiplicity/type I (α) error	What method has the research team selected to analyse the PRO data?	<p><i>PPI partners are not expected to contribute in the selection of methods for addressing multiple testing. However, they could ask the team to explain what PRO analysis method has been chosen and why.</i></p>		
SPRIT-20c-PRO Elaboration: state how missing data will be described and outline the methods for handling missing items or entire assessments (eg, approach to imputation and sensitivity analyses)	How is the research team going to analyse the PRO data? How will the team deal with missing data?	<p><i>PPI partners are not expected to plan how data will be analysed, but can question the trial team about the methods that will be used to handle missing data.</i></p>		
Monitoring				

Continued

Table 1 Continued

SPIRIT-PRO item number and description	Questions for PPI partner(s) to consider	Key considerations for PPI partner(s)	Considerations for the lay summary	Considerations for participant information sheet and consent form
SPIRIT-22-PRO Elaboration: state whether or not PRO data will be monitored during the study to inform the clinical care of individual trial participants and, if so, how this will be managed in a standardised way. Describe how this process will be explained to participants; for example, in the participant information sheet and consent form	Will questionnaire data be reviewed by the research or clinical team? If so, when? What happens if the PRO indicates patient deterioration or distress? Have the research team explained what sorts of scores would indicate distress or deterioration? How will participants be informed of this process? (ie, in the participant information sheet and consent form).	<p>▲ PPI partners can help develop the participant information sheet and consent form and any other process used to inform patients about how PRO data will be monitored during the study to inform the clinical care of individual trial participants.</p> <p>▲ PPI partners can question the team about their plan to manage concerning levels of psychological distress or physical symptoms that might require an immediate response.</p>		<p>What measures are in place to ensure patient distress or deterioration is identified, communicated to patient and dealt with it?</p> <p>If data will not be clinically reviewed, how concerns are going to be dealt with by the clinical research team. For instance, mobile phone to support (emergency number) and what resources are there to support participants.</p> <p>Include detailed plans for regular feedback to participants via letter/newsletter on PRO aspect of study.</p>

HRQL, Health-related quality of life; PPI, patient and public involvement; PRO, patient-reported outcome; SPIRIT, Standard Protocol Items; Recommendations for Interventional Trials.

SPIRIT-PRO guideline and glossary (figure 1). Following the PPI session, attendees commented on the wording and agreed on the penultimate version of the user-friendly SPIRIT-PRO Extension content. Broader feedback on final guidance was sought from two additional patient partners (RW/RS).

During the PPI session, patient partners discussed the design and content of a previously published diagram (PRO learn resource for patient advocates involved in coproduction of research or review, online supplemental appendix 1) on the PRO considerations for PPI partners in the design and review of trials collecting PROs.¹⁸ PPI partners highlighted key SPIRIT-PRO items and additional information that should be incorporated in the published diagram. These changes led to the development of the web-tool.

RESULTS

Seven PPI partners were involved in the codesign of two tools to promote the uptake and dissemination of the SPIRIT-PRO Extension guidance by patient partners involved in the codevelopment of clinical trials. PPI partners highlighted specific priorities and preferred formats. In addition, PPI partners contributed to the writing up of the discussion section and in particular around the benefits of the development of these tools.

User-friendly version of the SPIRIT-PRO Extension guidance

This tool was developed to adapt the SPIRIT-PRO Extension guidance to a user-friendly format for patient partners. The user-friendly tool (table 1) presents five different key items for PPI partners to consider while involved in the codesign and/or review of trials collecting PROs: (a) SPIRIT-PRO item number and description; (b) questions for PPI partner(s) to consider; (c) key considerations for PPI partner(s); (d) considerations for the lay summary and (e) considerations for the participant information sheet and consent form. A glossary (online supplemental appendix 2) was also codeveloped to aid PPI partners in the implementation of the user-friendly tool.

Web-based tool

The web-based tool, presented in concertina style, illustrates the main key items PPI partners considered most relevant from the user-friendly SPIRIT-PRO Extension version. The web-tool aimed at supporting the dissemination and uptake of the SPIRIT-PRO Extension by patient partners, provides PPI partners with six general PRO-specific questions to facilitate their role as codesigners and interaction with the trial team. PPI partners are not expected to answer these questions but to raise these questions with the research team while codeveloping the clinical trial.

The main six SPIRIT-PRO items included were: (a) does the team have a clear reason for assessing PROs in the trial? And has the team clearly stated the purpose of the research? (b) which questionnaire(s) are they

Research Spotlights Our Researchers Research Areas PhDs Institutes

Does the team have a clear reason for assessing PROs in the trial? Has the team clearly stated the purpose of the research?

- It is essential that the team has a clear rationale for assessment
- Has the team specified what exactly going to be measured by the PRO questionnaire? For instance; quality of life, physical function, pain and/or fatigue, etc.
- How do they plan to use the PRO data that they collect in the trial?

Which questionnaire(s) are they considering using? +

Are there any reasons why a patient might not be able to complete the PRO questionnaire? +

How often, when and where will patients be asked to complete the questionnaire(s)? +

What languages are the chosen questionnaire(s) available in? +

How will the team ensure that they collect high quality data that can meaningfully inform future patient care? +

Figure 2 Web-tool for patient advocates involved in coproduction of PRO research or review. PRO, patient-reported outcome.

considering using? (c) are there any reasons why a patient might not be able to complete the PRO questionnaire? (d) how often, when and where will patients be asked to complete the questionnaire(s)? (e) what languages are the chosen questionnaire(s) available in? and (f) how will the team ensure that they collect high quality data that can meaningfully inform future patient care? The diagram provides further detail to each question to help PPI partners ask more in depth questions and better understand the importance of capturing PROs in trials. In addition, the web-tool includes 'other considerations' and 'other resources' for PPI partners to facilitate their understanding and participation in the design of the trial. For instance, 'other considerations' includes key elements that should be covered in the participant information sheet for potential trial participants. 'Other resources' include web resources such as ePROVIDE and GRIPP 2 checklist.¹⁹ The webtool is available from the Centre for Patient Reported Outcomes Research website.²⁰ Figure 2 presents an overview of the codeveloped web-tool.

DISCUSSION

Two user-friendly tools were codesigned with the assistance of seven patient partners to assist PPI partners involved in the design or review of clinical trials and provide informed, patient-centred input into development of PRO aspects of clinical trial protocols. PPI in this research was essential to ensure that the tools were comprehensive and user friendly for PPI partners. In addition, it was essential to enhance the dissemination and uptake of the SPIRIT-PRO Extension guidance.

The involvement of PPI partners helped ensure that the tools focused on issues that matter most to them. PPI should go beyond involvement; it should be a platform for patients to influence, design processes, identify relevant content and to make decisions significant for and acceptable to end users.^{21 22} PPI partners raised important concerns related to the completion of PRO questionnaires such as: time needed to complete the PRO questionnaire(s) and frequency patients need to complete the questionnaire(s). Although these are covered by the SPIRIT-PRO Extension guidance, they were included in the patient information sheet section under the 'other resources' section.

Patients have recently advocated against regulatory agencies for approving oncology drugs based on surrogate endpoints rather than the value they add to patients' lives.^{23 24} In addition, patients frequently do not completely understand their diagnostics and are not aware of the side effects of the interventions, as they are occasionally not effectively communicated by healthcare professionals.²⁴ Therefore, patient and public awareness and their involvement can help tackle these issues.^{23 24} Currently, PRO stakeholders are making concerted efforts to incorporate the patients' experience into the drug development process, which has the potential to better inform shared decision-making.²⁵ For instance, the Food and Drug Administration is patient-focused drug development guidance to address how stakeholders can collect and include PROs from patients and caregivers in the development and regulation of medical products.²⁶ In 2016, the European Medicine Agency published

Appendix 2 to the guideline on the evaluation of anti-cancer medicinal products in man. Appendix 2 describes the use of PRO endpoints in oncology studies and the value of PRO data from the regulatory perspective.²⁷

PROs carry the 'voice' of the patients; hence, trials collecting PROs should include patients and carers as codesigners to inform PRO measure development, selection, and implementation and ensure that PRO data are analysed and published.^{21 28} Thus, maximising the impact on future patient benefit and reducing research waste. The design of trials collecting PROs without patient input can be considered unreasonable and unacceptable.^{9 21} PPI partners should be empowered to be involved in the design of trials collecting PROs and their content, and make decisions by using the two different tools developed, while following the SPIRIT-PRO Extension guidance. The strengths of the research include the participation of seven PPI partners, who were selected with a range of levels of experience and exposure to trial development to ensure the outputs were well-informed, but also accessible for new patients and public. Adherence to GRIPP 2 guidance to report PPI involvement in research was a further strength of the study.¹⁶ The tools presented in this manuscript were developed to aid patient partners in the codevelopment or review of clinical trials collecting PROs. Nonetheless, these tools have the potential to be used in other types of clinical studies in which the participation of patients and carers is essential.

However, the tools developed were not tested among patient partners with less trial experience or less experience with research, which could have helped in the refinement of the tools. A further limitation is that two PPI partners involved in the codevelopment of the user-friendly version of the SPIRIT-PRO Extension guidance were involved in the development of the original guidance. This previous knowledge and understanding of the SPIRIT-PRO items might have influenced the selection of lay vocabulary. However, to tackle these four additional PPI partners were included to agree on the best wording of the guidance. Patient partners were involved in the same way in both research projects. However, patient partners drove the agenda more during the codevelopment of the tools for patients as the aim of the research was to develop tools for them to use. An additional limitation is that PPI partners' perspectives may not be reflective of a larger patient population as the majority of the participants were oncology partners and only one carer was included.

In conclusion, the tools developed, if used appropriately, have the potential to facilitate the involvement of patient partners in providing informed input into the development of PRO aspects of clinical trial protocols, in accordance with the SPIRIT-PRO Extension guidelines.

Next steps

Feedback can be provided on the resource using an anonymised survey https://www.smartsurvey.co.uk/s/SPIRIT-PRO_Tools_for_patients/, which will help

inform future developments. We encourage PPI partners and researchers involved in the design or review of trials collecting PROs to provide further feedback to the research team.

Author affiliations

¹Institute of Applied Health Research, Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK

²Stakeholder Group, BBMRI-ERIC, Graz, Austria

³Central Clinical School, University of Sydney, Sydney, New South Wales, Australia

⁴QOL Office, University of Sydney, Sydney, New South Wales, Australia

⁵Centre for Patient Reported Outcomes, University of Birmingham, Birmingham, UK

⁶Consumer Forum, National Cancer Research Institute, London, UK

Twitter Samantha Cruz Rivera @samsamcr

Contributors SCR lead the conceptualisation, data curation, formal analysis, investigation, methodology and writing of the original draft. RS critically reviewed and edited the manuscript. GP contributed to the conceptualisation of the manuscript and reviewed the draft. PE, LG, LR and RV contributed to the conceptualisation of the manuscript. RW, RM-B, CR, OLA and AS contributed to the conceptualisation and reviewed and edited the manuscript. MC acquired funding, lead the conceptualisation and reviewed and edited the manuscript.

Funding This work was funded by an unrestricted educational research grant from UCB Pharma. Award/Grant number is not applicable.

Competing interests MC and AS receive funding from the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre and NIHR ARC West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, UCB Pharma. The views expressed in this article are those of the author(s) and not necessarily those of the NIHR, or the Department of Health and Social Care. MC has received personal fees from Astellas, Takeda, Merck, Daiichi Sankyo, Glaukos, GlaxoSmithKline and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. RM-B is supported by the Australian Government by a National Health and Medical Research. OLA declares personal fees from Gilead Sciences Ltd and GlaxoSmithKline outside the submitted work.

Patient consent for publication Not required.

Ethics approval Ethical approval for this study was gained from the University of Birmingham, UK (ERN_19-0939).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data sharing not applicable as no datasets generated and/or analysed for this study. All data relevant to the study are included in the article or uploaded as supplemental information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Samantha Cruz Rivera <http://orcid.org/0000-0002-1566-6804>

Rebecca Mercieca-Bebber <http://orcid.org/0000-0003-3708-9099>

Melanie Calvert <http://orcid.org/0000-0002-1856-837X>

REFERENCES

- 1 FDA. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims., 2009. Available: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf>
- 2 Wilson IB, Cleary P. Linking clinical variables with health-related quality of life. *JAMA* 1995;273:59.
- 3 UK Clinical Research Collaboration. Understanding clinical trials 2006. Available: https://www.ukcr.org/wp-content/uploads/2014/03/iCT_Booklet.pdf
- 4 Ahmed K, Kyte D, Keeley T, *et al.* Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPIC study protocol. *BMJ Open* 2016;6:e012863.
- 5 Retzer A, Keeley T, Ahmed K, *et al.* Evaluation of patient-reported outcome protocol content and reporting in UK cancer clinical trials: the EPIC study qualitative protocol. *BMJ Open* 2018;8:e017282.
- 6 Mercieca-Bebber R, Friedlander M, Kok P-S, *et al.* The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols. *Qual Life Res* 2016;25:2457–65.
- 7 Kyte D, Duffy H, Fletcher B, *et al.* Systematic evaluation of the patient-reported outcome (pro) content of clinical trial protocols. *PLoS One* 2014;9:e110229.
- 8 Mercieca-Bebber R, Friedlander M, Calvert M, *et al.* A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice. *J Patient Rep Outcomes* 2017;1:5.
- 9 Kyte D, Retzer A, Ahmed K, *et al.* Systematic evaluation of patient-reported outcome protocol content and reporting in cancer trials. *J Natl Cancer Inst* 2019;111:1170–8.
- 10 Schandelmaier S, Conen K, von Elm E, *et al.* Planning and reporting of quality-of-life outcomes in cancer trials. *Ann Oncol* 2015;26:1966–73.
- 11 Brundage M, Bass B, Davidson J, *et al.* Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. *Qual Life Res* 2011;20:653–64.
- 12 Mercieca-Bebber RL, Perreca A, King M, *et al.* Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: a systematic review of completeness of reporting and impact on interpretation. *Eur J Cancer* 2016;56:144–61.
- 13 Efficace F, Bottomley A, Osoba D, *et al.* Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials - does HRQOL evaluation in prostate cancer research inform clinical decision making? *J Clin Oncol* 2003;21:3502–11.
- 14 Dirven L, Taphoorn MJB, Reijneveld JC, *et al.* The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: a systematic review. *Eur J Cancer* 2014;50:2432–48.
- 15 Calvert M, Kyte D, Mercieca-Bebber R, *et al.* Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the spirit-pro extension. *JAMA* 2018;319:483–94.
- 16 Staniszewska S, Brett J, Simera I, *et al.* GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. *BMJ* 2017;358:j3453.
- 17 INVOLVE. About involve. Available: <https://www.invo.org.uk/about-involve/> [Accessed Oct 2020].
- 18 Calvert MaK, Derek. I'm a patient advocate involved in the design or review of a study using PROs. What should I consider? : CPROR, 2016. Available: <https://www.birmingham.ac.uk/Documents/college-meds/centres/PRO-Guide-for-Patient-Advocates.pdf>
- 19 ePROVIDE clinical support for clinical outcome assessments. Available: <https://eprovide.mapi-trust.org/>
- 20 Centre for patient reported outcomes research - PRO learn. Available: <https://www.birmingham.ac.uk/research/applied-health/research/prolearn/patient-advocates.aspx>
- 21 Wilson R. Patient led PROMs must take centre stage in cancer research. *Res Involv Engagem* 2018;4:7.
- 22 Selby P, Velikova G. Taking patient reported outcomes centre stage in cancer research - why has it taken so long? *Res Involv Engagem* 2018;4:25.
- 23 Crompton S. PROMs put patients at the heart of research and care, 2018. Available: <https://cancerworld.net/featured/proms-put-patients-at-the-heart-of-research-and-care/81>
- 24 Richards T. The responses to the "cancer drugs scandal" must fully involve patients-an essay by Tessa Richards. *BMJ* 2017;359:j4956.
- 25 Kluetz PG, O'Connor DJ, Soltys K. Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada. *Lancet Oncol* 2018;19:e267–74.
- 26 FDA patient-focused drug development guidance series for enhancing the incorporation of the patient's voice in medical product development and regulatory decision making, 2018. Available: <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm610279.htm> [Accessed Jan 2019].
- 27 European Medicines Agency. *Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. The use of patient-reported outcome (PRO) measures in oncology studies.* London: European Medicine Agency, 2016. https://www.ema.europa.eu/documents/other/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf
- 28 Haywood KL, Wilson R, Staniszewska S, *et al.* Using PROMs in healthcare: who should be in the driving seat-policy makers, health professionals, methodologists or patients? *Patient* 2016;9:495–8.